IMMUTEP Business Summary

Immutep Ltd (NASDAQ: IMMP) is a late-stage biotechnology firm specializing in the development of Lymphocyte Activation Gene-3 (LAG-3) immunotherapies for oncology and autoimmune diseases. The company operates on a pre-commercial business model, generating revenue through strategic licensing agreements, clinical milestone payments, and research grants. Its primary value driver is its lead candidate, eftilagimod alfa ("efti"), a first-in-class soluble LAG-3 protein currently in a pivotal Phase III trial (TACTI-004) for first-line non-small cell lung cancer (NSCLC). Immutep recently expanded its commercial footprint via a December 2025 licensing deal with Dr. Reddy’s Laboratories, securing a $20 million upfront payment and up to $349.5 million in potential milestones for emerging markets. In the competitive landscape, Immutep faces direct pressure from Bristol Myers Squibb (Opdualag), Merck & Co., and Regeneron; however, it distinguishes itself as the only player utilizing an MHC Class II agonist to activate antigen-presenting cells, whereas competitors primarily focus on anti-LAG-3 antagonist antibodies. The leadership team is anchored by Chief Scientific Officer Dr. Frédéric Triebel, the original discoverer of the LAG-3 gene (1990) and founder of Immutep S.A., which was acquired by the current entity in 2014. Chief Executive Officer Marc Voigt has led the company since the acquisition, bringing over 25 years of experience from Deutsche Life Science and Allianz. The executive suite is further supported by Chief Operating Officer Deanne Miller and Chief Medical Officer Dr. Stephan Winckels, who oversees the global clinical pipeline. The company is governed by a board chaired by Dr. Russell Howard and maintains a strong institutional investor base, including BNY Asset Management, Regal Partners, and Fidelity International. As of early 2026, the team has successfully extended its cash runway into mid-2027, supported by high-profile clinical collaborations with industry giants such as MSD (Merck) and Novartis.